This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Google Scholar Articles by Cardoso, F. Articles by Piccart-Gebhart, M. J. PubMed PubMed Citation Articles by Cardoso, F. Articles by Piccart-Gebhart, M. J.

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Fatima Cardoso, Laura Van't Veer, Emiel Rutgers, Sherene Loi, Stella Mook, Martine J. Piccart-Gebhart

From the Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, the Netherlands; and Peter MacCallum Cancer Centre, Melbourne, Australia

Corresponding author: M.J. Piccart-Gebhart, PhD, MD, Medical Oncology, Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium; e-mail: martine.piccart{at}bordet.be

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.

Supported by the European Commission Framework Programme VI, the Breast Cancer Research Foundation, the European Breast Cancer Conference (EBCC) Breast Cancer Working Group, the Fondation Belge Contre Le Cancer, the Susan G. Komen for the Cure Foundation, Jacqueline Seroussi Memorial Foundation for Cancer Research, the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group, the Center of Biomedical Genetics, the Dutch Health Care Insurance Board, and the Dutch National Genomic Initiative Cancer Genomics Program.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.